. Author manuscript; available in PMC: 2019 Sep 1.

Published in final edited form as: Breast Cancer Res Treat. 2018 May 22;171(2):325–334. doi: 10.1007/s10549-018-4828-5

Table 2.

Assessment Variables Reported in Pretreatment Questionnaire

Pretreatment assessment Variable		Patients Treated with Bevacizumab Plus Letrozole (n=112)
		# of Patients (%)	Mean ± Standard Deviation	Median (Range)
OARS IADL^a	Completely Independent	76 (67.9%)	13.2 ± 1.5	32 (6–32)
OARS Comorbidity	0 1 2 or more	76 (67.9%) 19 (17.0%) 17 (15.2%)
MOS^b	Activities of Daily Living		76.8 ± 26.5	90 (5–100)
	Social Activity		47.9 ± 9.6	50 (25–75)
Timed Up and Go	Seconds		13.0 ± 9.2	10 (2–60)
Falls in past 6 months	None 1 or more Unavailable	88 (78.6%) 22 (19.6%) 2 (1.8%)
Hearing	Excellent/Good Fair/Poor/Deaf Unavailable	97 (86.6%) 14 (12.5%) 1 (0.9%)
Vision	Excellent/Good Fair/Poor/Blind Unavailable	99 (88.4%) 12 (10.7%) 1 (0.9%)
MHI^c	Depression and Anxiety		78.3 ± 33.0	81 (21–100)
BOMC^d Cognition Score	<11 ≥11 Unavailable	108 (96.4%) 1 (0.9%) 3 (2.7%)
BMI (kg/m²)^e	<22 ≥30 Unavailable	17 (15.2%) 46 (41.1%) 49 (43.7%)
Weight Loss	Greater than 5% in the last 6 months	0 (0.0%)

^a:

Older Americans Resources and Services Scale—Instrumental Activities of Daily Living³²

^b:

Medical Outcomes Study³³

^c:

Mental Health Inventory³³

^d:

Blessed Orientation-Memory-Concentration¹⁶

^e:

Body Mass Index (kilogram/meter squared)